Global Moyamoya disease Market

Moyamoya disease Comprehensive Study by Type (Ischemic, Hemorrhagic, Epileptic, Other), Treatment (Non-Surgical {Anti-seizure medications, and Calcium channel blockers}, Surgical {Vascular bypass surgery, and Cerebral Revascularization }), Age Group (5 to 10 years in children, 30 to 50 years in adults, Other), Diagnosis (Cerebral angiogram, Magnetic resonance imaging (MRI), Magnetic resonance angiography (MRA), Computed tomography (CT), Positron emission tomography (PET), Electrocardiography ECG, Transcranial Doppler ultrasound), Surgical Procedure (Indirect {Encephalomyosynangiosis (EMS), Encephaloduroarteriosynangiosis (EDAS)}, Direct {Suturing of a scalp blood vessel, the superficial temporal artery}), Distribution channel (Hospital, Surgical Centers, Diagnostic clinics, Others) Players and Region - Global Market Outlook to 2027

Moyamoya disease Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Moyamoya diseases are commonly known as MMD disease, it is an idiopathic disease, rare cerebrovascular disease. In this disease, it mainly attacks blood vessels of the brain and the skull becomes blocked or narrowed, reducing blood flow to your brain. It can be categorized progressive in nature leading to recurrent stroke due to occlusion of the terminal internal carotid arteries. It can occur in any age but more chances in following age groups 5 to 10 years in children and 30 to 50 years in adults most peak incidence occur in this age group. The treatment found both surgical and non-surgical depending upon the type of disease and severity. There are various diagnostic methods are available to detect such a rare condition for early treatment.This growth is primarily driven by Increasing Diagnostic Awareness About Moyamoya Disease.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Diseases & Therapeutic Areas sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Abbott Laboratories (United States), Boston Scientific Corporation (United States), Cephalon Inc (United States), Novartis (Switzerland), Cordis Corporation (United States), Eisai Co Ltd (Japan), GE Healthcare (United States), Johnson and Johnson (United States), GlaxoSmithKline (United Kingdom), Medtronic plc (Ireland), Merck & Co Inc (United States), Sanofi (France) and Siemens Healthineers (Germany), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 24th November 2019, Novartis announced a merger with US-based Biopharmaceutical Company for USD 85.00 per share in cash. Novartis company recently merged with The Medicines Company to enhance its business and develop in the market.
On 13th December 2019, Boston Scientific Corporation announced US Food and drug administration (FDA) approved 510(k) clearance for EXALT Model D Single-Use Duodenoscope. It is first and only FDA cleared single-use (disposable) duodenoscope on the market and was granted.The growing neurological diseases increasing demand for diagnostic devices and different treatments in the market. The leading firms have strong competition to acquire the market share in the market. The options like mergers and acquisitions also available to change market strategies.

Regulatory Insights:
The non-surgical treatment used for Moyamoya disease in that majorly anti-coagulation and anti-platelet agents used for the prevention of further strokes, especially in stenotic vessels (where further infarction can occur if occlusion progresses) the above medications are not approved by the FDA for specifically to treat Moyamoya disease.

Influencing Trend:
Acceptance of Surgical Treatments In Comparison to Non-Surgical

Market Growth Drivers:
Increasing Diagnostic Awareness About Moyamoya Disease

Challenges:
One of the Life-Threatening Disease, Therefore Increases Mortality Rate

Restraints:
High Cost Associated With Diagnostic Methods And Surgical Treatments

Opportunities:
Growing Awareness About Available Treatments Of Moyamoya Disease

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Moyamoya disease Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Moyamoya disease Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Moyamoya disease players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Moyamoya disease Study Sheds Light on
— The Moyamoya disease Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Moyamoya disease industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Moyamoya disease industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Ischemic
  • Hemorrhagic
  • Epileptic
  • Other
By Treatment
  • Non-Surgical {Anti-seizure medications, and Calcium channel blockers}
  • Surgical {Vascular bypass surgery, and Cerebral Revascularization }

By Age Group
  • 5 to 10 years in children
  • 30 to 50 years in adults
  • Other

By Diagnosis
  • Cerebral angiogram
  • Magnetic resonance imaging (MRI)
  • Magnetic resonance angiography (MRA)
  • Computed tomography (CT)
  • Positron emission tomography (PET)
  • Electrocardiography ECG
  • Transcranial Doppler ultrasound

By Surgical Procedure
  • Indirect {Encephalomyosynangiosis (EMS), Encephaloduroarteriosynangiosis (EDAS)}
  • Direct {Suturing of a scalp blood vessel, the superficial temporal artery}

By Distribution channel
  • Hospital
  • Surgical Centers
  • Diagnostic clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Diagnostic Awareness About Moyamoya Disease
    • 3.3. Market Challenges
      • 3.3.1. One of the Life-Threatening Disease, Therefore Increases Mortality Rate
    • 3.4. Market Trends
      • 3.4.1. Acceptance of Surgical Treatments In Comparison to Non-Surgical
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Moyamoya disease, by Type, Treatment, Age Group, Diagnosis, Surgical Procedure, Distribution channel and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Moyamoya disease (Value)
      • 5.2.1. Global Moyamoya disease by: Type (Value)
        • 5.2.1.1. Ischemic
        • 5.2.1.2. Hemorrhagic
        • 5.2.1.3. Epileptic
        • 5.2.1.4. Other
      • 5.2.2. Global Moyamoya disease by: Treatment (Value)
        • 5.2.2.1. Non-Surgical {Anti-seizure medications, and Calcium channel blockers}
        • 5.2.2.2. Surgical {Vascular bypass surgery, and Cerebral Revascularization }
      • 5.2.3. Global Moyamoya disease by: Age Group (Value)
        • 5.2.3.1. 5 to 10 years in children
        • 5.2.3.2. 30 to 50 years in adults
        • 5.2.3.3. Other
      • 5.2.4. Global Moyamoya disease by: Diagnosis (Value)
        • 5.2.4.1. Cerebral angiogram
        • 5.2.4.2. Magnetic resonance imaging (MRI)
        • 5.2.4.3. Magnetic resonance angiography (MRA)
        • 5.2.4.4. Computed tomography (CT)
        • 5.2.4.5. Positron emission tomography (PET)
        • 5.2.4.6. Electrocardiography ECG
        • 5.2.4.7. Transcranial Doppler ultrasound
      • 5.2.5. Global Moyamoya disease by: Surgical Procedure (Value)
        • 5.2.5.1. Indirect {Encephalomyosynangiosis (EMS), Encephaloduroarteriosynangiosis (EDAS)}
        • 5.2.5.2. Direct {Suturing of a scalp blood vessel, the superficial temporal artery}
      • 5.2.6. Global Moyamoya disease by: Distribution channel (Value)
        • 5.2.6.1. Hospital
        • 5.2.6.2. Surgical Centers
        • 5.2.6.3. Diagnostic clinics
        • 5.2.6.4. Others
      • 5.2.7. Global Moyamoya disease Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Moyamoya disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boston Scientific Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cephalon Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cordis Corporation (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eisai Co Ltd (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GE Healthcare (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson and Johnson (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Medtronic plc (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Merck & Co Inc (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sanofi (France)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Siemens Healthineers (Germany)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Moyamoya disease Sale, by Type, Treatment, Age Group, Diagnosis, Surgical Procedure, Distribution channel and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Moyamoya disease (Value)
      • 7.2.1. Global Moyamoya disease by: Type (Value)
        • 7.2.1.1. Ischemic
        • 7.2.1.2. Hemorrhagic
        • 7.2.1.3. Epileptic
        • 7.2.1.4. Other
      • 7.2.2. Global Moyamoya disease by: Treatment (Value)
        • 7.2.2.1. Non-Surgical {Anti-seizure medications, and Calcium channel blockers}
        • 7.2.2.2. Surgical {Vascular bypass surgery, and Cerebral Revascularization }
      • 7.2.3. Global Moyamoya disease by: Age Group (Value)
        • 7.2.3.1. 5 to 10 years in children
        • 7.2.3.2. 30 to 50 years in adults
        • 7.2.3.3. Other
      • 7.2.4. Global Moyamoya disease by: Diagnosis (Value)
        • 7.2.4.1. Cerebral angiogram
        • 7.2.4.2. Magnetic resonance imaging (MRI)
        • 7.2.4.3. Magnetic resonance angiography (MRA)
        • 7.2.4.4. Computed tomography (CT)
        • 7.2.4.5. Positron emission tomography (PET)
        • 7.2.4.6. Electrocardiography ECG
        • 7.2.4.7. Transcranial Doppler ultrasound
      • 7.2.5. Global Moyamoya disease by: Surgical Procedure (Value)
        • 7.2.5.1. Indirect {Encephalomyosynangiosis (EMS), Encephaloduroarteriosynangiosis (EDAS)}
        • 7.2.5.2. Direct {Suturing of a scalp blood vessel, the superficial temporal artery}
      • 7.2.6. Global Moyamoya disease by: Distribution channel (Value)
        • 7.2.6.1. Hospital
        • 7.2.6.2. Surgical Centers
        • 7.2.6.3. Diagnostic clinics
        • 7.2.6.4. Others
      • 7.2.7. Global Moyamoya disease Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Moyamoya disease: by Type(USD Million)
  • Table 2. Moyamoya disease Ischemic , by Region USD Million (2016-2021)
  • Table 3. Moyamoya disease Hemorrhagic , by Region USD Million (2016-2021)
  • Table 4. Moyamoya disease Epileptic , by Region USD Million (2016-2021)
  • Table 5. Moyamoya disease Other , by Region USD Million (2016-2021)
  • Table 6. Moyamoya disease: by Treatment(USD Million)
  • Table 7. Moyamoya disease Non-Surgical {Anti-seizure medications, and Calcium channel blockers} , by Region USD Million (2016-2021)
  • Table 8. Moyamoya disease Surgical {Vascular bypass surgery, and Cerebral Revascularization } , by Region USD Million (2016-2021)
  • Table 9. Moyamoya disease: by Age Group(USD Million)
  • Table 10. Moyamoya disease 5 to 10 years in children , by Region USD Million (2016-2021)
  • Table 11. Moyamoya disease 30 to 50 years in adults , by Region USD Million (2016-2021)
  • Table 12. Moyamoya disease Other , by Region USD Million (2016-2021)
  • Table 13. Moyamoya disease: by Diagnosis(USD Million)
  • Table 14. Moyamoya disease Cerebral angiogram , by Region USD Million (2016-2021)
  • Table 15. Moyamoya disease Magnetic resonance imaging (MRI) , by Region USD Million (2016-2021)
  • Table 16. Moyamoya disease Magnetic resonance angiography (MRA) , by Region USD Million (2016-2021)
  • Table 17. Moyamoya disease Computed tomography (CT) , by Region USD Million (2016-2021)
  • Table 18. Moyamoya disease Positron emission tomography (PET) , by Region USD Million (2016-2021)
  • Table 19. Moyamoya disease Electrocardiography ECG , by Region USD Million (2016-2021)
  • Table 20. Moyamoya disease Transcranial Doppler ultrasound , by Region USD Million (2016-2021)
  • Table 21. Moyamoya disease: by Surgical Procedure(USD Million)
  • Table 22. Moyamoya disease Indirect {Encephalomyosynangiosis (EMS), Encephaloduroarteriosynangiosis (EDAS)} , by Region USD Million (2016-2021)
  • Table 23. Moyamoya disease Direct {Suturing of a scalp blood vessel, the superficial temporal artery} , by Region USD Million (2016-2021)
  • Table 24. Moyamoya disease: by Distribution channel(USD Million)
  • Table 25. Moyamoya disease Hospital , by Region USD Million (2016-2021)
  • Table 26. Moyamoya disease Surgical Centers , by Region USD Million (2016-2021)
  • Table 27. Moyamoya disease Diagnostic clinics , by Region USD Million (2016-2021)
  • Table 28. Moyamoya disease Others , by Region USD Million (2016-2021)
  • Table 29. South America Moyamoya disease, by Country USD Million (2016-2021)
  • Table 30. South America Moyamoya disease, by Type USD Million (2016-2021)
  • Table 31. South America Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 32. South America Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 33. South America Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 34. South America Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 35. South America Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 36. Brazil Moyamoya disease, by Type USD Million (2016-2021)
  • Table 37. Brazil Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 38. Brazil Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 39. Brazil Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 40. Brazil Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 41. Brazil Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 42. Argentina Moyamoya disease, by Type USD Million (2016-2021)
  • Table 43. Argentina Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 44. Argentina Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 45. Argentina Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 46. Argentina Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 47. Argentina Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 48. Rest of South America Moyamoya disease, by Type USD Million (2016-2021)
  • Table 49. Rest of South America Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 50. Rest of South America Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 51. Rest of South America Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 52. Rest of South America Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 53. Rest of South America Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 54. Asia Pacific Moyamoya disease, by Country USD Million (2016-2021)
  • Table 55. Asia Pacific Moyamoya disease, by Type USD Million (2016-2021)
  • Table 56. Asia Pacific Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 57. Asia Pacific Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 58. Asia Pacific Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 59. Asia Pacific Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 60. Asia Pacific Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 61. China Moyamoya disease, by Type USD Million (2016-2021)
  • Table 62. China Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 63. China Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 64. China Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 65. China Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 66. China Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 67. Japan Moyamoya disease, by Type USD Million (2016-2021)
  • Table 68. Japan Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 69. Japan Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 70. Japan Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 71. Japan Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 72. Japan Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 73. India Moyamoya disease, by Type USD Million (2016-2021)
  • Table 74. India Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 75. India Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 76. India Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 77. India Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 78. India Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 79. South Korea Moyamoya disease, by Type USD Million (2016-2021)
  • Table 80. South Korea Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 81. South Korea Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 82. South Korea Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 83. South Korea Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 84. South Korea Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 85. Taiwan Moyamoya disease, by Type USD Million (2016-2021)
  • Table 86. Taiwan Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 87. Taiwan Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 88. Taiwan Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 89. Taiwan Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 90. Taiwan Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 91. Australia Moyamoya disease, by Type USD Million (2016-2021)
  • Table 92. Australia Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 93. Australia Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 94. Australia Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 95. Australia Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 96. Australia Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 97. Rest of Asia-Pacific Moyamoya disease, by Type USD Million (2016-2021)
  • Table 98. Rest of Asia-Pacific Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 99. Rest of Asia-Pacific Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 100. Rest of Asia-Pacific Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 101. Rest of Asia-Pacific Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 102. Rest of Asia-Pacific Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 103. Europe Moyamoya disease, by Country USD Million (2016-2021)
  • Table 104. Europe Moyamoya disease, by Type USD Million (2016-2021)
  • Table 105. Europe Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 106. Europe Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 107. Europe Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 108. Europe Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 109. Europe Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 110. Germany Moyamoya disease, by Type USD Million (2016-2021)
  • Table 111. Germany Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 112. Germany Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 113. Germany Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 114. Germany Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 115. Germany Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 116. France Moyamoya disease, by Type USD Million (2016-2021)
  • Table 117. France Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 118. France Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 119. France Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 120. France Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 121. France Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 122. Italy Moyamoya disease, by Type USD Million (2016-2021)
  • Table 123. Italy Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 124. Italy Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 125. Italy Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 126. Italy Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 127. Italy Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 128. United Kingdom Moyamoya disease, by Type USD Million (2016-2021)
  • Table 129. United Kingdom Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 130. United Kingdom Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 131. United Kingdom Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 132. United Kingdom Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 133. United Kingdom Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 134. Netherlands Moyamoya disease, by Type USD Million (2016-2021)
  • Table 135. Netherlands Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 136. Netherlands Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 137. Netherlands Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 138. Netherlands Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 139. Netherlands Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 140. Rest of Europe Moyamoya disease, by Type USD Million (2016-2021)
  • Table 141. Rest of Europe Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 142. Rest of Europe Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 143. Rest of Europe Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 144. Rest of Europe Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 145. Rest of Europe Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 146. MEA Moyamoya disease, by Country USD Million (2016-2021)
  • Table 147. MEA Moyamoya disease, by Type USD Million (2016-2021)
  • Table 148. MEA Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 149. MEA Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 150. MEA Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 151. MEA Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 152. MEA Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 153. Middle East Moyamoya disease, by Type USD Million (2016-2021)
  • Table 154. Middle East Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 155. Middle East Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 156. Middle East Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 157. Middle East Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 158. Middle East Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 159. Africa Moyamoya disease, by Type USD Million (2016-2021)
  • Table 160. Africa Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 161. Africa Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 162. Africa Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 163. Africa Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 164. Africa Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 165. North America Moyamoya disease, by Country USD Million (2016-2021)
  • Table 166. North America Moyamoya disease, by Type USD Million (2016-2021)
  • Table 167. North America Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 168. North America Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 169. North America Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 170. North America Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 171. North America Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 172. United States Moyamoya disease, by Type USD Million (2016-2021)
  • Table 173. United States Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 174. United States Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 175. United States Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 176. United States Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 177. United States Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 178. Canada Moyamoya disease, by Type USD Million (2016-2021)
  • Table 179. Canada Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 180. Canada Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 181. Canada Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 182. Canada Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 183. Canada Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 184. Mexico Moyamoya disease, by Type USD Million (2016-2021)
  • Table 185. Mexico Moyamoya disease, by Treatment USD Million (2016-2021)
  • Table 186. Mexico Moyamoya disease, by Age Group USD Million (2016-2021)
  • Table 187. Mexico Moyamoya disease, by Diagnosis USD Million (2016-2021)
  • Table 188. Mexico Moyamoya disease, by Surgical Procedure USD Million (2016-2021)
  • Table 189. Mexico Moyamoya disease, by Distribution channel USD Million (2016-2021)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Moyamoya disease: by Type(USD Million)
  • Table 204. Moyamoya disease Ischemic , by Region USD Million (2022-2027)
  • Table 205. Moyamoya disease Hemorrhagic , by Region USD Million (2022-2027)
  • Table 206. Moyamoya disease Epileptic , by Region USD Million (2022-2027)
  • Table 207. Moyamoya disease Other , by Region USD Million (2022-2027)
  • Table 208. Moyamoya disease: by Treatment(USD Million)
  • Table 209. Moyamoya disease Non-Surgical {Anti-seizure medications, and Calcium channel blockers} , by Region USD Million (2022-2027)
  • Table 210. Moyamoya disease Surgical {Vascular bypass surgery, and Cerebral Revascularization } , by Region USD Million (2022-2027)
  • Table 211. Moyamoya disease: by Age Group(USD Million)
  • Table 212. Moyamoya disease 5 to 10 years in children , by Region USD Million (2022-2027)
  • Table 213. Moyamoya disease 30 to 50 years in adults , by Region USD Million (2022-2027)
  • Table 214. Moyamoya disease Other , by Region USD Million (2022-2027)
  • Table 215. Moyamoya disease: by Diagnosis(USD Million)
  • Table 216. Moyamoya disease Cerebral angiogram , by Region USD Million (2022-2027)
  • Table 217. Moyamoya disease Magnetic resonance imaging (MRI) , by Region USD Million (2022-2027)
  • Table 218. Moyamoya disease Magnetic resonance angiography (MRA) , by Region USD Million (2022-2027)
  • Table 219. Moyamoya disease Computed tomography (CT) , by Region USD Million (2022-2027)
  • Table 220. Moyamoya disease Positron emission tomography (PET) , by Region USD Million (2022-2027)
  • Table 221. Moyamoya disease Electrocardiography ECG , by Region USD Million (2022-2027)
  • Table 222. Moyamoya disease Transcranial Doppler ultrasound , by Region USD Million (2022-2027)
  • Table 223. Moyamoya disease: by Surgical Procedure(USD Million)
  • Table 224. Moyamoya disease Indirect {Encephalomyosynangiosis (EMS), Encephaloduroarteriosynangiosis (EDAS)} , by Region USD Million (2022-2027)
  • Table 225. Moyamoya disease Direct {Suturing of a scalp blood vessel, the superficial temporal artery} , by Region USD Million (2022-2027)
  • Table 226. Moyamoya disease: by Distribution channel(USD Million)
  • Table 227. Moyamoya disease Hospital , by Region USD Million (2022-2027)
  • Table 228. Moyamoya disease Surgical Centers , by Region USD Million (2022-2027)
  • Table 229. Moyamoya disease Diagnostic clinics , by Region USD Million (2022-2027)
  • Table 230. Moyamoya disease Others , by Region USD Million (2022-2027)
  • Table 231. South America Moyamoya disease, by Country USD Million (2022-2027)
  • Table 232. South America Moyamoya disease, by Type USD Million (2022-2027)
  • Table 233. South America Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 234. South America Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 235. South America Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 236. South America Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 237. South America Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 238. Brazil Moyamoya disease, by Type USD Million (2022-2027)
  • Table 239. Brazil Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 240. Brazil Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 241. Brazil Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 242. Brazil Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 243. Brazil Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 244. Argentina Moyamoya disease, by Type USD Million (2022-2027)
  • Table 245. Argentina Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 246. Argentina Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 247. Argentina Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 248. Argentina Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 249. Argentina Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 250. Rest of South America Moyamoya disease, by Type USD Million (2022-2027)
  • Table 251. Rest of South America Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 252. Rest of South America Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 253. Rest of South America Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 254. Rest of South America Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 255. Rest of South America Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 256. Asia Pacific Moyamoya disease, by Country USD Million (2022-2027)
  • Table 257. Asia Pacific Moyamoya disease, by Type USD Million (2022-2027)
  • Table 258. Asia Pacific Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 259. Asia Pacific Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 260. Asia Pacific Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 261. Asia Pacific Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 262. Asia Pacific Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 263. China Moyamoya disease, by Type USD Million (2022-2027)
  • Table 264. China Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 265. China Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 266. China Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 267. China Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 268. China Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 269. Japan Moyamoya disease, by Type USD Million (2022-2027)
  • Table 270. Japan Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 271. Japan Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 272. Japan Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 273. Japan Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 274. Japan Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 275. India Moyamoya disease, by Type USD Million (2022-2027)
  • Table 276. India Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 277. India Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 278. India Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 279. India Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 280. India Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 281. South Korea Moyamoya disease, by Type USD Million (2022-2027)
  • Table 282. South Korea Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 283. South Korea Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 284. South Korea Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 285. South Korea Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 286. South Korea Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 287. Taiwan Moyamoya disease, by Type USD Million (2022-2027)
  • Table 288. Taiwan Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 289. Taiwan Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 290. Taiwan Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 291. Taiwan Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 292. Taiwan Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 293. Australia Moyamoya disease, by Type USD Million (2022-2027)
  • Table 294. Australia Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 295. Australia Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 296. Australia Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 297. Australia Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 298. Australia Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 299. Rest of Asia-Pacific Moyamoya disease, by Type USD Million (2022-2027)
  • Table 300. Rest of Asia-Pacific Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 301. Rest of Asia-Pacific Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 302. Rest of Asia-Pacific Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 303. Rest of Asia-Pacific Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 304. Rest of Asia-Pacific Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 305. Europe Moyamoya disease, by Country USD Million (2022-2027)
  • Table 306. Europe Moyamoya disease, by Type USD Million (2022-2027)
  • Table 307. Europe Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 308. Europe Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 309. Europe Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 310. Europe Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 311. Europe Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 312. Germany Moyamoya disease, by Type USD Million (2022-2027)
  • Table 313. Germany Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 314. Germany Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 315. Germany Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 316. Germany Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 317. Germany Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 318. France Moyamoya disease, by Type USD Million (2022-2027)
  • Table 319. France Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 320. France Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 321. France Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 322. France Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 323. France Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 324. Italy Moyamoya disease, by Type USD Million (2022-2027)
  • Table 325. Italy Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 326. Italy Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 327. Italy Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 328. Italy Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 329. Italy Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 330. United Kingdom Moyamoya disease, by Type USD Million (2022-2027)
  • Table 331. United Kingdom Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 332. United Kingdom Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 333. United Kingdom Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 334. United Kingdom Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 335. United Kingdom Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 336. Netherlands Moyamoya disease, by Type USD Million (2022-2027)
  • Table 337. Netherlands Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 338. Netherlands Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 339. Netherlands Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 340. Netherlands Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 341. Netherlands Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 342. Rest of Europe Moyamoya disease, by Type USD Million (2022-2027)
  • Table 343. Rest of Europe Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 344. Rest of Europe Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 345. Rest of Europe Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 346. Rest of Europe Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 347. Rest of Europe Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 348. MEA Moyamoya disease, by Country USD Million (2022-2027)
  • Table 349. MEA Moyamoya disease, by Type USD Million (2022-2027)
  • Table 350. MEA Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 351. MEA Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 352. MEA Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 353. MEA Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 354. MEA Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 355. Middle East Moyamoya disease, by Type USD Million (2022-2027)
  • Table 356. Middle East Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 357. Middle East Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 358. Middle East Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 359. Middle East Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 360. Middle East Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 361. Africa Moyamoya disease, by Type USD Million (2022-2027)
  • Table 362. Africa Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 363. Africa Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 364. Africa Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 365. Africa Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 366. Africa Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 367. North America Moyamoya disease, by Country USD Million (2022-2027)
  • Table 368. North America Moyamoya disease, by Type USD Million (2022-2027)
  • Table 369. North America Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 370. North America Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 371. North America Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 372. North America Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 373. North America Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 374. United States Moyamoya disease, by Type USD Million (2022-2027)
  • Table 375. United States Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 376. United States Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 377. United States Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 378. United States Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 379. United States Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 380. Canada Moyamoya disease, by Type USD Million (2022-2027)
  • Table 381. Canada Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 382. Canada Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 383. Canada Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 384. Canada Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 385. Canada Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 386. Mexico Moyamoya disease, by Type USD Million (2022-2027)
  • Table 387. Mexico Moyamoya disease, by Treatment USD Million (2022-2027)
  • Table 388. Mexico Moyamoya disease, by Age Group USD Million (2022-2027)
  • Table 389. Mexico Moyamoya disease, by Diagnosis USD Million (2022-2027)
  • Table 390. Mexico Moyamoya disease, by Surgical Procedure USD Million (2022-2027)
  • Table 391. Mexico Moyamoya disease, by Distribution channel USD Million (2022-2027)
  • Table 392. Research Programs/Design for This Report
  • Table 393. Key Data Information from Secondary Sources
  • Table 394. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Moyamoya disease: by Type USD Million (2016-2021)
  • Figure 5. Global Moyamoya disease: by Treatment USD Million (2016-2021)
  • Figure 6. Global Moyamoya disease: by Age Group USD Million (2016-2021)
  • Figure 7. Global Moyamoya disease: by Diagnosis USD Million (2016-2021)
  • Figure 8. Global Moyamoya disease: by Surgical Procedure USD Million (2016-2021)
  • Figure 9. Global Moyamoya disease: by Distribution channel USD Million (2016-2021)
  • Figure 10. South America Moyamoya disease Share (%), by Country
  • Figure 11. Asia Pacific Moyamoya disease Share (%), by Country
  • Figure 12. Europe Moyamoya disease Share (%), by Country
  • Figure 13. MEA Moyamoya disease Share (%), by Country
  • Figure 14. North America Moyamoya disease Share (%), by Country
  • Figure 15. Global Moyamoya disease share by Players 2021 (%)
  • Figure 16. Global Moyamoya disease share by Players (Top 3) 2021(%)
  • Figure 17. Global Moyamoya disease share by Players (Top 5) 2021(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 20. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 21. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 22. Boston Scientific Corporation (United States) Revenue: by Geography 2021
  • Figure 23. Cephalon Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. Cephalon Inc (United States) Revenue: by Geography 2021
  • Figure 25. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 27. Cordis Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Cordis Corporation (United States) Revenue: by Geography 2021
  • Figure 29. Eisai Co Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Eisai Co Ltd (Japan) Revenue: by Geography 2021
  • Figure 31. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 32. GE Healthcare (United States) Revenue: by Geography 2021
  • Figure 33. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 34. Johnson and Johnson (United States) Revenue: by Geography 2021
  • Figure 35. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2021
  • Figure 37. Medtronic plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 38. Medtronic plc (Ireland) Revenue: by Geography 2021
  • Figure 39. Merck & Co Inc (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck & Co Inc (United States) Revenue: by Geography 2021
  • Figure 41. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 42. Sanofi (France) Revenue: by Geography 2021
  • Figure 43. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Siemens Healthineers (Germany) Revenue: by Geography 2021
  • Figure 45. Global Moyamoya disease: by Type USD Million (2022-2027)
  • Figure 46. Global Moyamoya disease: by Treatment USD Million (2022-2027)
  • Figure 47. Global Moyamoya disease: by Age Group USD Million (2022-2027)
  • Figure 48. Global Moyamoya disease: by Diagnosis USD Million (2022-2027)
  • Figure 49. Global Moyamoya disease: by Surgical Procedure USD Million (2022-2027)
  • Figure 50. Global Moyamoya disease: by Distribution channel USD Million (2022-2027)
  • Figure 51. South America Moyamoya disease Share (%), by Country
  • Figure 52. Asia Pacific Moyamoya disease Share (%), by Country
  • Figure 53. Europe Moyamoya disease Share (%), by Country
  • Figure 54. MEA Moyamoya disease Share (%), by Country
  • Figure 55. North America Moyamoya disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Boston Scientific Corporation (United States)
  • Cephalon Inc (United States)
  • Novartis (Switzerland)
  • Cordis Corporation (United States)
  • Eisai Co Ltd (Japan)
  • GE Healthcare (United States)
  • Johnson and Johnson (United States)
  • GlaxoSmithKline (United Kingdom)
  • Medtronic plc (Ireland)
  • Merck & Co Inc (United States)
  • Sanofi (France)
  • Siemens Healthineers (Germany)
Additional players considered in the study are as follows:
Sunovion Pharmaceuticals (United States) , UCB Pharma Ltd (Belgium) , Bausch Health Companies (Canada)
Select User Access Type

Key Highlights of Report


Nov 2022 215 Pages 63 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Moyamoya disease Market Quantitative research analysis
Global Moyamoya disease Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Moyamoya disease Market are Abbott Laboratories (United States), Boston Scientific Corporation (United States), Cephalon Inc (United States), Novartis (Switzerland), Cordis Corporation (United States), Eisai Co Ltd (Japan), GE Healthcare (United States), Johnson and Johnson (United States), GlaxoSmithKline (United Kingdom), Medtronic plc (Ireland), Merck & Co Inc (United States), Sanofi (France) and Siemens Healthineers (Germany) etc.

Know More About Global Moyamoya disease Market Report?

Have a Query? Click Here

Other Related Reports

Bacteriophages Therapy Comprehensive Study by Type (Lytic, Lysogenic), Application (Diagnostic, Antimicrobial Drug Discovery, Veterinary Medicines, Others), Treatment (Oral, External Application, Sur...
$ 3650
Systemic Mycoses Comprehensive Study by Type (Paracoccidioides, Blastomyces, Histoplasma, Coccidiode), Fungi (Dermatophytes, Yeasts, Molds), Drugs (Amphotericin B, Amphotericin B Itraconazole, Amphot...
$ 3750
Neurotrophic Keratitis Treatment Comprehensive Study by Type (Drugs, Devices, Surgery), Application (Hospitals, Ambulatory Surgical Centers, Others), Route of Administration (Oral, Topical), Distribu...
$ 3450
Metastatic Bone Disease Treatment Comprehensive Study by Type (Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy), Application (Hospitals, Specialty Clinics, Ambulatory Sur...
$ 3750
Digital Brain Therapy Comprehensive Study by Type (Transcranial random noise stimulation (tRNS), Transcranial direct current stimulation (tDCS), Transcranial alternating current stimulation (tACS), T...
$ 3750
Dementia Care Comprehensive Study by Type (Memory Exercise & Activity Products, Daily Reminder Products, Bathroom Safety Products, Dining Aids Communication Products, Personal Safety Products Others)...
$ 3450